(IN BRIEF) Evotec SE announced that Bayer has initiated a Phase 2 clinical study for BAY 3401016, a Semaphorin-3A-targeting monoclonal antibody being developed as a potential therapeutic option for patients with Alport syndrome. As part of the companies’ kidney disease … Read the full press release
Posted in Business, Germany, Healthcare, Investment, News, Pharma & Biotech, Science, Technology
Tagged Alport syndrome, ASSESS study, BAY 3401016, Bayer, clinical development, COL4A3, COL4A4, COL4A5, end stage renal disease, Evotec, Evotec Announces Phase 2 Advancement of BAY 3401016 for Alport Syndrome in Collaboration with Bayer, milestone payment, monoclonal antibody, phase 2 trial, podocytes, rare kidney disease, Sema3A, Semaphorin-3A
(IN BRIEF) EIB is providing up to €37.5 million in venture debt to Xeltis as part of a new €50 million financing package that will help bring aXess, the company’s regenerative vascular access conduit, to market. The investment follows excellent … Read the full press release
Posted in Banks, Energy, Gas & Oil, European Union, Financial, Healthcare, Infrastructure & Utilities, Investment, Luxembourg, Netherlands, News, Pharma & Biotech
Tagged Alexander Goemans, aXess, commercialization funding, EIB, Eliane Schutte, end stage renal disease, Endogenous Tissue Restoration, EQT Life Sciences, ETR platform, EU pivotal trial, European Investment Bank, hemodialysis, Invest-NL, InvestEU, LSP Health Economics Fund 2, MedTech innovation, PFAS free polymer technology, regenerative implants, Robert de Groot, US pivotal trial, vascular access conduit, venture-debt financing, Xabg, Xeltis, Xeltis Advances Regenerative Implant Portfolio with Strong Backing from EIB and Existing Investors
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?